- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02688153
EDWARDS INTUITY Valve System CADENCE Study (CADENCE)
A Randomized Comparison of the EDWARDS INTUITY Valve System anD commErcially Available Aortic Bioprostheses in Subjects uNdergoing surgiCal Aortic Valve replacEment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized study comparing the cross-clamp time (XCT) and cardiopulmonary bypass time (CPBT) of the EDWARDS INTUITY valve system with any commercially available stented aortic bioprosthesis, in patients with logistic EuroSCORE 1 ≥ 6 undergoing elective surgical aortic valve replacement surgery with concomitant coronary bypass grafts.
Additionally, the aim is to gather sufficient data to quantify the effect size of short term patient benefit outcomes previously identified from literature and finally to explore additional healthcare resource utilization or health economic endpoints.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Pessac, France, 33604
- CHU Bordeaux, Hopital Haut-Leveque
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion:
- ≥18 years of age
- aortic stenosis / mixed aortic stenosis and aortic insufficiency
- SAVR+CABG (1-4 distal anastomoses)
- Log. EuroSCORE ≥6
- NYHA Class ≥II
Exclusion (i.a.):
- pure aortic insufficiency
- pre-existing prosthetic heart valve or ring
- congenital true bicuspid / unicuspid aortic valve
- LVEF <20%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: EDWARDS INTUITY
EDWARDS INTUITY Valve System, Model 8300A
|
To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR & CABG.
Other Names:
|
|
Active Comparator: Stented aortic bioprostheses
|
In comparison to control valves available on the market.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average Subject Time Spent on Cardiopulmonary Cross Clamp
Time Frame: At time of surgery, an average of 1.5 hours
|
Cardiopulmonary cross clamp time is the amount of time that the patient's aorta (blood vessel) is clamped by a surgical instrument used in cardiac surgery.
This allows the normal blood flow to be sent to an artificial heart and lung machine to keep it at a constant temperature and oxygen level.
|
At time of surgery, an average of 1.5 hours
|
|
Average Amount of Time Subject Spent on Cardiopulmonary Bypass
Time Frame: At time of surgery, an average of 2 hours
|
Cardiopulmonary bypass time is the amount of time that the patient's blood circulates through an artificial heart and lung machine during cardiac surgery.
|
At time of surgery, an average of 2 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Change From Baseline in New York Heart Association (NYHA) Class at 2 Years.
Time Frame: Baseline and 2 Years
|
The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. Patients with cardiac disease but without resulting limitation of physical activity. Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. |
Baseline and 2 Years
|
|
Subject's Average Mean Gradients (mmHg) Measurements Over Time.
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.
Gradients are evaluated by echocardiography over time.
Mean gradient values depend on the size and type of valve.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subject's Average Peak Gradients (mmHg) Measurements Over Time.
Time Frame: 30 days, 3 months, 6 months, 1 year, 2 year
|
Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.
Gradients are evaluated by echocardiography over time.
|
30 days, 3 months, 6 months, 1 year, 2 year
|
|
Subject's Effective Orifice Area (EOA) Measurement Over Time.
Time Frame: 30 days, 3 months, 6 months, 1 year, 2 year
|
Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve.
Effective orifice area is evaluated by echocardiography over time.
|
30 days, 3 months, 6 months, 1 year, 2 year
|
|
Subject's Effective Orifice Area Index (EOAI) Measurement Over Time.
Time Frame: 30 days, 3 months, 6 months, 1 year, 2 year
|
Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area.
Effective orifice area index is evaluated by echocardiography over time.
|
30 days, 3 months, 6 months, 1 year, 2 year
|
|
Amount of Aortic Valvular Regurgitation Over Time.
Time Frame: 30 days, 3 months, 6 months, 1 year, 2 year
|
Aortic valvular regurgitation occurs when the aortic valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it.
Aortic valvular regurgitation is evaluated by echocardiography over time.
It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.
|
30 days, 3 months, 6 months, 1 year, 2 year
|
|
Conversion of Edwards INTUITY Surgical Aortic Valve to Control During Surgery.
Time Frame: Prior to Surgery
|
Subjects randomized to the Edwards INTUITY group that were converted to the control group and received commercially available surgical aortic heart valves during surgery.
|
Prior to Surgery
|
|
Subjects Who Required a Thoracic Resternotomy Over Time
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of Subjects who had a surgical opening of their chest after their initial aortic heart valve surgery shown over various time points.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects Who Received a Permanent Pacemaker Over Time.
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of Subjects who received a Permanent Pacemaker shown over various time points.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects With a Major Paravalvular Leak (OPC) Over Time
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of subjects who experienced a Major Paravalvular Leak (OPC) shown over various time points. Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing. Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. A major paravalvular leak (OPC)are any events of leak that required surgical intervention or were considered an serious adverse event. |
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects Who Experienced Major Bleeding Over Time.
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of subjects who experienced Major Bleeding shown over various time points.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects Who Experienced Respiratory Failure Over Time
Time Frame: 30 days, 3 Months , 6 Months, 1 Year, 2 Years.
|
Number of subjects who experienced a Respiratory Failure shown over various time points.
Respiratory failure happens when not enough oxygen passes from your lungs to your blood.
|
30 days, 3 Months , 6 Months, 1 Year, 2 Years.
|
|
Subjects With a Cerebral Vascular Accident or Permanent Stroke Over Time
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of subjects who experienced a Cerebral Vascular Accident or Permanent Stroke shown over various time points.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects With Renal Failure Over Time
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of subjects who experienced Renal (kidney) Failure shown over various time points.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects With Endocarditis Over Time
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of subjects who experienced Endocarditis shown over various time points.
Endocarditis is an infection of the endocardium, which is the inner lining of your heart chambers and heart valves.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects With a Deep Sternal Would Infection Over Time
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of subjects who experienced a Deep Sternal Wound Infection shown over various time points.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects With a Myocardial Infarction Over Time
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of subjects who experienced a Myocardial Infarction shown over various time points.
A Myocardial infarction, commonly known as a heart attack, occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects With a Thromboembolism Over Time
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of subjects who experienced a Thromboembolism shown over various time points.
A thromboembolism is an obstruction of a blood vessel by a blood clot that has become dislodged from another site in the circulation.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects With a Cardiac Tamponade Over Time
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of subjects who experienced a Cardiac Tamponade shown over various time points.
Cardiac tamponade is when fluid in the pericardium (the sac around the heart) builds up and results in compression (squeezing) of the heart.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects With a Cardiac Reoperation for Any Reason Over Time
Time Frame: 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
Number of subjects who experienced a Cardiac reoperation for any reason shown over various time points.
|
30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subjects Who Died Intraoperatively
Time Frame: Surgery
|
Number of subjects who died during surgery.
|
Surgery
|
|
Subject's Average Score on the EQ-5D- Quality of Life Questionnaire Over Time
Time Frame: Baseline, 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
The EQ-5D is a standardized questionnaire that asks subjects to rate themselves (no problems, some problems, extreme problems) on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
The scale is indexed and ranges from a minimum of 0.275 and a maximum of 1.000.
A lower number indicates the participants experiences more problems and a higher number indicates the participants experiences fewer problems.
|
Baseline, 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subject's Average Score SF-12 - Quality of Life Questionnaire Over Time
Time Frame: Baseline, 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
The Medical Outcomes Study Short-Form 12 (SF-12) - Physical Component Summary (PCS) and Mental Component Summary (MCS). The SF-12 questionnaire scale ranges from 100, which reflects the best health status to 0, which reflects the worse health status. Subject's Average Score at Baseline and at each follow-up interval until 2 year - SF-12. |
Baseline, 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Subject's Average Score on the KCCQ - Quality of Life Questionnaire Over Time
Time Frame: Baseline, 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.
Scores range from 0-100, in which higher scores reflect better health status.
Subjects took this questionnaire at baseline, 30 days, 3 Months, 6 Months, 1 Year, and 2 Years.
|
Baseline, 30 days, 3 Months, 6 Months, 1 Year, 2 Years.
|
|
Health Care Utilization
Time Frame: Day of surgical procedure through discharge from the hospital, an average of 2 weeks
|
The average amount of time the subjects spent in the intensive care unit, the intermediate care length of stay, and the average total length of hospital stay after their heart valve replacement procedure.
|
Day of surgical procedure through discharge from the hospital, an average of 2 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Prof. Labrousse, MD, Chu Bordeaux - Hôpital Haut-Lévêque
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-11 (Other Identifier: AP HM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
National Institute of Cardiology, Warsaw, PolandThe Institute of Bioorganic Chemistry, Polish Academy of SciencesRecruitingAortic Stenosis | Low-gradient Aortic StenosisPoland
-
MiRusRecruitingAortic Stenosis | Symptomatic Severe Native Aortic StenosisUnited States
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Hospices Civils de LyonCompleted
-
Abbott Medical DevicesCompletedSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Edwards LifesciencesRecruitingAortic Valve Stenosis | Aortic Stenosis, CalcificUnited States, Australia, Switzerland, Canada, Japan, Netherlands
-
University of AlbertaNot yet recruitingAortic Stenosis | Severe Aortic StenosisCanada
-
Medtronic CardiovascularCompleted
-
Rede Optimus Hospitalar SARecruitingSevere Aortic StenosisSwitzerland, France, Germany, Austria, Czechia, Italy, Netherlands
Clinical Trials on EDWARDS INTUITY
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Assistance Publique Hopitaux De MarseilleCompletedSevere Aortic Valve DiseaseFrance
-
University of PadovaEdwards Lifesciences; Azienda Ospedaliera di Padova; Ospedale San Bortolo di...Suspended
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With InsufficiencyAustria, Germany
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Valve DiseaseGermany
-
Deutsches Herzzentrum MuenchenRecruitingCerebral Embolization During TAVI Using Balloon-expandable vs. Self-expandable ValvesGermany
-
Edwards LifesciencesActive, not recruitingMitral Regurgitation | Mitral Insufficiency | Mitral Repair | Mitral Valve | Annuloplasty | Edwards CardiobandSwitzerland, Germany, Italy
-
Edwards LifesciencesActive, not recruitingTricuspid Valve InsufficiencySwitzerland, Germany, Greece, Italy
-
Claret MedicalCompletedSevere Symptomatic Calcified Native Aortic Valve StenosisUnited States, Germany
-
Edwards LifesciencesActive, not recruitingMitral Valve Regurgitation (Degenerative or Functional)United States, Canada